Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic

Abstract

Background To ensure safe delivery of oncologic care during the COVID-19 pandemic, telemedicine has been rapidly adopted. However, little data exist on the impact of telemedicine on quality and accessibility of oncologic care. This study assessed whether conducting an office visit for thoracic oncology patients via telemedicine affected time to treatment initiation and accessibility. Methods This was a retrospective cohort study of patients with thoracic malignancies seen by a multidisciplinary team during the first surge of COVID-19 cases in Philadelphia (March 1 to June 30, 2020). Patients with an index visit for a new phase of care, defined as a new diagnosis, local recurrence, or newly discovered metastatic disease, were included. Results 240 distinct patients with thoracic malignancies were seen: 132 patients (55.0%) were seen initially in-person vs 108 (45.0%) via telemedicine. The majority of visits were for a diagnosis of a new thoracic cancer (87.5%). Among newly diagnosed patients referred to the thoracic oncology team, the median time from referral to initial visit was significantly shorter amongst the patients seen via telemedicine vs. in-person (median 5.0 vs. 6.5 days, p < 0.001). Patients received surgery (32.5%), radiation (24.2%), or systemic therapy (30.4%). Time from initial visit to treatment initiation by modality did not differ by telemedicine vs in-person: surgery (22 vs 16 days, p = 0.47), radiation (27.5 vs 27.5 days, p = 0.86, systemic therapy (15 vs 13 days, p = 0.45). Conclusions Rapid adoption of telemedicine allowed timely delivery of oncologic care during the initial surge of the COVID19 pandemic by a thoracic oncology multi-disciplinary clinic.

Impact of the COVID-19 pandemic on psychosocial outcomes among women experiencing breast health delays in New York City

“…While the impact of these delays on oncologic outcomes is unknown, delays in treatment for breast cancer have been found to increase mortality [16][17]. Our study is similar to previous studies that have identi ed a large proportion of breast cancer patients reporting treatment delays due to the COVID-19 pandemic [18][19][20][21][22].…”

Clinical applications of telemedicine services using a regional telemedicine platform for cancer treatment: a cross-sectional study

“…Teleconsultation can effectively solve the problem that patients in rural areas cannot get effective treatment. Currently, telemedicine has been maturely applied in many specialized diseases, including the remote psychological consultation and telecare of cancer patients [ 27 , 28 ]. However, existing research works mainly consist of review analysis and theoretical research and focus on tele-health management of cancer patients, and there has been little detailed research on the application process of the teleconsultation waiting time, teleconsultation duration and on the evaluation of the effectiveness of teleconsultations.…”